Volunteer in vaccine test dies in Brazil
Print Edition
A VOLUNTEER in clinical trials of the COVID-19 vaccine developed by Oxford University has died in Brazil, officials announced on Wednesday, although media reports said he had received a placebo, not the test vaccine.
It is the first death reported in the various coronavirus vaccine trials taking place worldwide. But organizers of the study said an independent review had concluded there were no safety concerns and that testing of the vaccine, developed with pharmaceutical firm AstraZeneca, would continue.
Media reports said the volunteer was a 28-year-old doctor working on the front lines of the pandemic who died of complications from COVID-19.
Brazilian newspaper Globo said he was in the control group and had received a placebo rather than the test vaccine, citing sources close to the trials.
鈥淔ollowing careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue,鈥 Oxford said in a statement.
AstraZeneca said medical confidentiality meant it could not give details on any individual volunteer, but that an independent review had 鈥渘ot led to any concerns about continuation of the ongoing study.鈥
Brazil鈥檚 national health regulator, Anvisa, confirmed it had been notified of the case on October 19.
Oxford and AstraZeneca previously had to suspend testing of the vaccine in September when a volunteer in Britain developed an unexplained illness.
Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
